Kryger Capital LLC Buys New Position in Drugs Made In America Acquisition II Corp. $DMII

Kryger Capital LLC bought a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 309,729 shares of the company’s stock, valued at approximately $3,088,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Magnetar Financial LLC acquired a new position in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $26,730,000. Glazer Capital LLC bought a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $23,264,000. First Trust Capital Management L.P. acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter worth approximately $20,474,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Drugs Made In America Acquisition II in the first quarter worth approximately $19,960,000. Finally, Hudson Bay Capital Management LP bought a new position in Drugs Made In America Acquisition II during the 4th quarter valued at $19,493,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Drugs Made In America Acquisition II Trading Up 0.1%

Drugs Made In America Acquisition II stock opened at $10.10 on Friday. Drugs Made In America Acquisition II Corp. has a 1 year low of $9.86 and a 1 year high of $10.11. The business has a 50 day simple moving average of $10.08.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.